{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:55:40Z","timestamp":1788357340257,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaip.2025.04.015","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T12:27:13Z","timestamp":1744892833000},"page":"1707-1716.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3485-9775","authenticated-orcid":false,"given":"Chun-Tse","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chien","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Won","family":"Suk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.04.015_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-020-00785-1","article-title":"Asthma epidemiology and risk factors","volume":"42","author":"Stern","year":"2020","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaip.2025.04.015_bib3","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jaci.2024.07.029","article-title":"Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: real-world US ADVANTAGE study","volume":"154","author":"Bleecker","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.015_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/cea.12179","article-title":"Frequent exacerbators\u2014a distinct phenotype of severe asthma","volume":"44","author":"Kupczyk","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.04.015_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2014present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2025.04.015_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.015_bib7","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.015_bib8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.015_bib9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.04.015_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2500\/aap.2024.45.240018","article-title":"Real-world effectiveness of dupilumab versus benralizumab and mepolizumab","volume":"45","author":"Bleecker","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.04.015_bib11","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1513\/AnnalsATS.202306-566OC","article-title":"Comparative effectiveness of mepolizumab, benralizumab, and dupilumab among patients with difficult-to-control asthma: a multicenter retrospective propensity-matched analysis","volume":"21","author":"Kearney","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2025.04.015_bib12","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation","volume":"151","author":"Akenroye","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.015_bib13","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jaip.2024.02.034","article-title":"Smaller differences in the comparative effectiveness of biologics in reducing asthma-related hospitalizations compared with overall exacerbations","volume":"12","author":"Akenroye","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.015_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.jaip.2025.04.015_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.curtheres.2019.100571","article-title":"Dupilumab in the treatment of moderate to severe asthma: an evidence-based review","volume":"91","author":"Rathinam","year":"2019","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.jaip.2025.04.015_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax-2021-217032","article-title":"Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study","volume":"78","author":"Soremekun","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.04.015_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111457","article-title":"Intention to treat and per protocol analyses: differences and similarities","volume":"173","author":"Molero-Calafell","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaip.2025.04.015_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.anai.2021.08.416","article-title":"Asthma biologics: real-world effectiveness, impact of switching biologics, and predictors of response","volume":"127","author":"Abbas","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.015_bib19","article-title":"A pragmatic guide to choosing biologic therapies in severe asthma","volume":"17","author":"Kavanagh","year":"2021","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.jaip.2025.04.015_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107414","article-title":"Biologics in severe asthma: a pragmatic approach for choosing the right treatment for the right patient","volume":"218","author":"Rogers","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.04.015_bib21","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.015_bib22","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.015_bib23","first-page":"152","article-title":"Association between peripheral eosinophils and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"131","author":"Okauchi","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jaip.2025.04.015_bib24","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.015_bib25","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/pds.5258","article-title":"New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: a review of reporting practices","volume":"30","author":"Luijken","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaip.2025.04.015_bib26","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/02770903.2018.1502301","article-title":"Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data","volume":"56","author":"Ortega","year":"2019","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2025.04.015_bib27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2025.04.015_bib28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/resp.14520","article-title":"Biologics for severe asthma\u2014which, when and why?","volume":"28","author":"Shah","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2025.04.015_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.arbres.2024.10.006","article-title":"Asthma-COPD overlap\u2014a gateway to biological treatment","volume":"61","author":"Padilla-Galo","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jaip.2025.04.015_bib30","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.alit.2024.11.003","article-title":"Prevalence and clinical impact of asthma-COPD overlap in severe asthma","volume":"74","author":"Wakazono","year":"2025","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2025.04.015_bib31","article-title":"DUPIXENT\u00ae (dupilumab) injection, for subcutaneous use","year":"2024","journal-title":"Prescribing information (Reference ID: 5453512)"},{"key":"10.1016\/j.jaip.2025.04.015_bib32","first-page":"756","article-title":"An introduction to g methods","volume":"46","author":"Naimi","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jaip.2025.04.015_bib33","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/10543406.2020.1757692","article-title":"The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring","volume":"30","author":"Dong","year":"2020","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.jaip.2025.04.015_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2022.12.068","article-title":"Tezepelumab-ekko improved asthma control and asthma symptom in adults with uncontrolled and severe asthma in real-life","volume":"151","author":"Gupta","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825003721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825003721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:41:12Z","timestamp":1755650472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825003721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2213219825003721"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.04.015","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}